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Abstract
Background: We evaluated the expression of human trophoblastic cell-surface marker (Trop-2) and the potential
of hRS7 - a humanized monoclonal anti-Trop-2 antibody - as a therapeutic strategy against treatment-refractory
human uterine (UMMT) and ovarian (OMMT) carcinosarcoma cell lines.
Materials and methods: Trop-2 expression was evaluated by immunohistochemistry (IHC) in paraffin-embedded
tumor tissues, by real-time polymerase-chain-reaction (RT-PCR) and flow-cytometry in cell lines. Sensitivity to hRS7
antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity was tested using 5-hour
chromium-release assays against UMMT and OMMT cells.
Results: Trop-2 expression was elevated in 9 of 26 (35%) UMMT and 8 of 14 (57%) OMMT tissues tested by IHC.
Positivity for Trop-2 mRNA by RT-PCR and surface expression by flow cytometry were detected in 2 of 4 cell lines,
with high positivity noted in OMMT-ARK-2. OMMT-ARK-2 was highly sensitive to hRS7 ADCC (range: 34.7-41.0%; P <
0.001) with negligible cytotoxicity seen in the absence of hRS7 or in the presence of control antibody (range: 1.1-
2.5%). Human IgG did not significantly inhibit ADCC while human complement increased, hRS7-mediated-
cytotoxicity against OMMT-ARK-2.
Conclusion: Trop-2 is overexpressed in a proportion of UMMT and OMMT, and hRS7 may represent a novel,
potentially highly effective treatment option for patients with treatment-refractory carcinosarcomas overexpressing
Trop-2.
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Background
Carcinosarcomas, also known as Mixed Mullerian
Tumors (MMT), of the female genital tract are rare
tumors that most commonly arise in the uterus, fol-
lowed by the ovaries, fallopian tubes, and the vagina [1].
The pathogenesis of carcinosarcomas remains under
debate, but an increasing body of evidence supports the
origin of both elements from a common epithelial cell
line that undergoes sarcomatous dedifferentiation, rather
than two independent progenitors [2]. Carcinosarcomas
are histologically comprised of malignant epithelial and
mesenchymal components and may be classified based
on the nature of their mesenchymal elements. Tumors
with “homologous” mesenchymal components differenti-
ate towards tissues physiologically native to the primary
site (e.g. leiomyosarcoma component), while heterolo-
gous tumors contain mesenchymal components that are
physiologically foreign to the primary site (e.g. chondro-
sarcoma component).
Uterine cancer is the most prevalent gynecologic
malignancy and the 4
th most prevalent cancer among
United States women, with an estimated 43,470 new
cases and 7,950 cancer-related deaths in 2010 [3].
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cies and have an estimated recurrence rate of 40-60%
[4], with approximately 35% of patients having extra-
uterine disease at diagnosis. Although surgical debulking
is the mainstay of treatment, the high rate of tumor
recurrence and a poor median survival of 16-40 months
after diagnosis suggest a need for improved adjuvant
treatment [5,6].
Cancer of the ovary is the 9
th most common malig-
nancy and the 5
th leading cause of cancer-related death
among U.S. women, with an estimated 28,880 new cases
and 13,850 associated deaths in 2010 [3]. Carcinosarco-
mas comprise less than 1-2% of these tumors [4], with
most individuals having nodal metastases at diagnosis
and 75% of women being found to have stage III or IV
disease at surgical staging. Ovarian carcinosarcoma por-
tends a worse prognosis than uterine carcinosarcoma,
with a median survival rate of 8-32 months and recur-
rence rates of 50-100% [4,6]. Cytoreductive surgery fol-
lowed by combination platinum-based chemotherapy
appears to confer the best survival benefits, with atten-
dant notable morbidity risks and continued dismal long-
term survival data.
There is a clear need to better understand the molecu-
lar basis of carcinosarcomas and to develop more effec-
tive treatment modalities against these aggressive
tumors. Trop-2 (also referred to as EGP-1, TACSTD2,
M1S1, and GA733-1) is a monomeric transmembrane
cell surface glycoprotein that was originally identified in
human placental trophoblastic tissue. It is expressed by
several human epithelial cancers but has limited expres-
sion in normal human cells [7]. Little is known about
the physiologic role of Trop-2 and the nature of its role
as an oncogene remains unclear. Trop-2 has been impli-
cated in activation of the ERK/MAPK pathway, leading
to downstream alterations in cell proliferation, migra-
tion, invasion, and survival [8]. Clinically, Trop-2 over-
expression has been associated with increased tumor
invasiveness and decreased overall survival in multiple
types of human carcinomas. Our group has previously
identified Trop-2 overexpression in serous ovarian can-
cer and uterine serous papillary carcinoma (USPC), two
notably aggressive, treatment-resistant gynecologic
malignancies. We have also identified Trop-2 as an
independent marker for decreased survival in patients
with epithelial ovarian carcinomas [9,10].
The differential expression of Trop-2 in cancers com-
pared to normal tissue, its association with clinically
important tumor behavior, and its histologic accessibility
as a transmembrane receptor make it an attractive target
for immunotherapy. Importantly, a murine monoclonal
antibody (mAb), mRS7, generated by hybridoma tech-
nology against Trop-2, has been shown to be effective
as a radiolabeled, as well as drug- and toxin-conjugated,
immunotherapeutic agent in xenograft cancer models
[11-15]. In this study we aimed to investigate the poten-
tial of hRS7, a humanized anti-Trop-2 monoclonal anti-
body, in the treatment of uterine and ovarian
carcinosarcomas.
Materials and methods
Trop-2 Immunostaining of Formalin-Fixed Tumor Tissues
Carcinosarcoma specimens (26 uterine and 14 ovarian),
normal ovarian, and endometrial control tissues were
evaluated by standard immunohistochemical staining
(IHC) on formalin-fixed tumor tissues for Trop-2 sur-
face expression. Patient characteristics from which
tumor and normal samples were obtained are described
in Table 1. IHC staining for Trop-2 were performed on
4-μm-thick sections of formalin-fixed, paraffin-
embedded tissue with purified goat polyclonal antibody
against the recombinant human Trop-2 extracellular
domain (R&D Systems, Inc., Minneapolis, MN; diluted
1:100), as described previously [9].
Establishment of Carcinosarcoma Cell Lines
Study approval was obtained from the Institutional
Review Board and informed consent was obtained from
all patients, per institutional guidelines. Fresh, surgical
tumor biopsies were collected and patients were staged
according to the International Federation of Gynecolo-
gists and Obstetricians 1988 operative staging system.
Two primary uterine carcinosarcoma cell lines (UMMT-
ARK-1 and UMMT-ARK-2) and two primary ovarian
carcinosarcoma cell lines (OMMT-ARK-1 and OMMT-
ARK-2) were established after sterile processing of surgi-
cal specimens as previously described [9,10]. Briefly,
tumor tissue was mechanically minced to portions no
Table 1 Patient Characteristics
Pathology and Tissue Type
(number)
Age in
Years
Race Stage
Mean (SD) AA
1 C
2 I II III IV
Formalin Fixed NEC
3(5) 66 (4) 3 2
Formalin Fixed NOVA
4 (3) 67 (6) 1 2
Formalin Fixed UMMT and
OMMT
UMMT (26) 66 (9) 10 16 14 4 5 3
OMMT (14) 72 (7) 5 9 4 3 5 2
Carcinosarcoma cell lines
Primary UMMT (2) 58 (12) 1 1 1 1
Primary OMMT (2) 67 (9) 1 1 1 1
1AA - African-American
2 C - Caucasian
3NEC - Normal Endometrial Cells
4NOVA - Normal Ovarian Cells
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3 in an enzyme solution made of
0.14% collagenase type I (Sigma) and 0.01% DNase
(Sigma, 2000 KU/mg) in RPMI 1640, and incubated in
the same solution in a magnetic stirring apparatus for
an hour at room temperature. Enzymatically dissociated
cells were then washed twice in RPMI 1640 with 10%
fetal bovine serum and maintained in RPMI supplemen-
ted with 10% fetal bovine serum, 200 μg/ml of penicillin
and 200 μg/ml of streptomycin at 37°C, 5% CO2 in 75
cm
2 tissue culture flasks or Petri dishes (Corning). After
seeding on plasticware for 48-72 hours, nonadherent
cells and contaminant inflammatory cells were gently
removed from the culture by multiple washings with
PBS. Both UMMTs were homologous and established
from uterine biopsies of chemotherapy naïve patients at
the time of staging surgery. UMMT-ARK-1 and
UMMT-ARK-2 were established from patients harbor-
ing FIGO stage I and FIGO stage II disease, respectively.
Of the OMMTs, one was homologous and one heterolo-
gous; both were obtained from metastatic sites in
patients harboring recurrent, chemotherapy-resistant
disease. These patients were initially diagnosed with
FIGO stage II (OMMT-ARK-2) and FIGO stage IV
(OMMT-ARK-1) ovarian cancer. Each cell line demon-
strated high resistance to multiple chemotherapeutic
agents including carboplatin, cisplatin, paclitaxel, doxor-
ubicin, ifosfamide, gemcitabine and topotecan when
tested in vitro by chemotherapy resistance assays
(Extreme Drug Resistant (EDR) assay, Oncotech, Irvine,
CA; Chemo Fx, Precision Therapeutics Inc., Pittsburgh,
PA. Data not shown). Source-patient characteristics and
initial staging data of these cell lines are described in
Table 1.
Quantitative Real-Time Polymerase Chain Reaction
RNA isolation from normal endometrium, ovarian
epithelial control tissues and each primary carcinosar-
coma cell line was performed using TRIzol Reagent
(Invitrogen) following manufacturer instructions, as pre-
viously described [9]. Since Trop-2 is an intron-less
gene, all RNA samples were treated with TURBO
DNase enzyme (TURBO DNAfree Kit; Ambion, Inc.,
Applied Biosystem Business, CA) to remove contaminat-
ing DNA. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) Assay on Demand Hs99999905_m1 (Applied
Biosystems, Foster City, CA) was an endogenous control
used to normalize variations in cDNA quantities
between samples. The qRT-PCR was performed in
d u p l i c a t eb yu s i n gap r i m e rs e ta n dp r o b es p e c i f i cf o r
Trop-2 (ie, Trop2-EX56, forward: CGCCTTGGG
TTTAAATTATTTGATGAGT; reverse: GCTACTACA-
TAGGCCCAGTTAACAA). Quantitative real-time PCR
(qRT-PCR) was performed with a 7500 Real-time PCR
System per manufacturer protocols (Applied Biosystems)
to evaluate Trop-2 expression in all samples. In brief,
complementary DNA obtained from 50 ng of total RNA
was amplified in a 25-μl PCR reaction following the
manufacturer’s recommended protocol and amplification
steps: denaturation for 10 min at 95°C followed by 40
cycles of denaturation at 95°C for 15 s and annealing
extension at 60°C for 1 min. The comparative threshold
cycle (CT) method was used to determine gene expres-
sion in each sample relative to the value observed in a
control cell line known to express Trop-2.
Flow Cytometry
The humanized anti-Trop-2 monoclonal antibody, hRS7
(Immunomedics, Inc., Morris Plains, NJ), was used for
flow cytometry studies. Each of the primary cell lines
obtained from the patients described above was stained
with 5 μg/mL of hRS7; similarly, 5 μg/mL of the chi-
meric anti-CD20 mAb rituximab (Rituxan, Genentech,
San Francisco, CA) was used as a negative control. A
goat anti-human F(ab)2 immunoglobulin (BioSource
International, Camarillo, CA) was used as a secondary
reagent. Analysis was conducted with FACScan, using
Cell Quest software (Becton Dickinson, Franklin Lakes,
NJ).
Tests for Antibody Dependent Cell Cytotoxicity (ADCC)
A standard 5-hour chromium (
51Cr) release assay was
performed to measure the cytotoxic reactivity of Ficoll-
PaqueTM PLUS (GE Healthcare, Uppsala, Sweden)
separated peripheral blood lymphocytes (PBLs) obtained
from several healthy donors against each cell line. The
release of
51Cr from the target cells was measured as
evidence of tumor cell lysis after exposure of tumor
cells to 10 μg/mL of hRS7. Controls included the incu-
bation of target cells alone as well as cells with PBLs
alone or mAb alone. Rituximab was used as a negative
control for hRS7 in all bioassays. ADCC was calculated
as the percentage of killing of target cells observed with
hRS7 plus effector cells compared with
51Cr release
from target cells incubated alone.
Test for Complement-Mediated Target Cell Lysis and
Gamma (g) -Globulin Inhibition
To evaluate the potential inhibition of ADCC against
UMMT and OMMT cell lines by physiologic human
plasma concentrations of g-globulin, human plasma was
added in the presence or absence of effector PBLs in a
1 : 2r a t i o .T h i sh u m a np l a s m aw a su s e da sas o u r c eo f
complement to test for complement-mediated target cell
lysis. A standard 5 h
51Cr release assay was again used
to assess the degree of cell lysis. In some experiments,
heat-inactivated human plasma (56°C for 60 minutes)
w a sa d d e di nt h ep r e s e n c eo fe f f e c t o rP B L s .C o n t r o l s
included the incubation of target cells alone or with
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used as a control mAb.
Statistical Analysis
For qRT-PCR data, the right skewing was removed by
taking copy number ratios relative to the lowest-expres-
sing normal endometrial cells (NEC) and normal ovarian
sample (NOVA) (relative copy number), log2 transform-
ing them to ΔCTs, and comparing the results by means
of unequal-variance t-test for carcinosarcomas versus
controls. Group means with 95% confidence intervals
(CIs) were calculated by computing them on the ΔCTs
and then reverse-transforming the results to obtain
means (with 95% CIs) of mRNA relative expression. Dif-
ferences in Trop-2 expression by flow cytometry were
analyzed by unpaired t-tests, and a P value of < 0.05
between samples was considered to be significant. The
Wilcoxon rank-sum (WRS) test was used to compare
carcinosarcomas against controls for differences in IHC
Trop-2 staining intensities. Sample-type differences were
expressed as odds ratios accompanied by 95% confidence
limits. Kruskal-Wallis test and chi-square analyses were
used to evaluate differences in hRS7-induced ADCC
levels in primary tumor cell lines. Statistical analysis was
performed using PASW Version 18 (SPSS, Chicago, IL).
Results
Trop-2 Expression by Immunohistochemistry of Uterine
and Ovarian Carcinosarcomas
We performed immunohistochemical analysis on forma-
lin-fixed, paraffin-embedded tumor tissue from a set of
40 patients harboring uterine (UMMT, 26 patients) and
ovarian (OMMT, 14 patients) carcinosarcomas. As
representatively shown in Figure 1 and reported in
Table 2, we found membranous positivity for Trop-2 in
9 of the 26 (35%) UMMT and 8 of the 14 (57%)
OMMT samples tested. The intensity of Trop-2 staining
was significantly higher among the tumor specimens
compared with normal endometrial cells (Figure 1) and
ovarian controls (WRS P ≤ 0.005). Of the positive
UMMT samples, 2 of the 9 specimens had a low posi-
tivity (1+) for Trop-2 protein, while the remaining speci-
mens showed moderate (2+ in 4 samples) or strong (3+
in 3 samples) Trop-2 positivity. Among the positive
OMMT samples, 2 of the 8 specimens showed low posi-
tivity (1+) for Trop-2 protein, while the remaining IHC
specimens showed moderate (2+ in 3 samples) or strong
(3+ in 3 samples) Trop-2 positivity. Without exception,
Trop-2 positivity was detected only in the epithelial
component of the carcinosarcoma specimens.
Trop-2 Transcript Levels in Carcinosarcomas
The ovarian and uterine carcinosarcoma cell lines were
tested for Trop-2 expression by qRT-PCR. Table 1
shows the histopathologic characteristics of the patients
from whom the cell lines were established. Trop-2
expression was significantly higher in two cell lines
(UMMT-ARK-1 and OMMT-ARK-2) compared with
normal control tissues (Table 3, P = 0.02). Among the
carcinosarcomas tested, UMMT-ARK-1 demonstrated a
low mRNA relative expression for Trop-2 (65.7) while
OMMT-ARK-2 demonstrated a high mRNA relative
expression for Trop-2 (13,032). Negligible Trop-2
expression by qRT-PCR was detected in the other cell
lines, with UMMT-ARK-2 and OMMT-ARK-1 having
0.012 and 0.453 mRNA relative expression respectively
(Table 3, P = 0.93).
Trop-2 Surface Expression by Flow Cytometry in Primary
Carcinosarcoma Cell Lines
To determine whether increased expression of Trop-2
mRNA corresponded with increased Trop-2 cell surface
protein expression, we performed flow cytometry on all
primary cell lines. Trop-2 surface expression by flow
cytometry was found to significantly correlate with
Trop-2 mRNA relative expression in all cell lines (Table
3). The difference in Trop-2 surface protein expression
between cell lines with low/negligible Trop-2 expression
and those with positive Trop-2 expression, as tested by
flow cytometry, was statistically significant (P =0 . 0 4 )a s
well as mRNA relative expression between cell lines
with low/negligible Trop-2 expression and those with
positive Trop-2 expression (p < 0.05).
Figure 1 Representative Trop2 immunostain in ovarian and
uterine MMT and control normal tissues. Upper left panel:
Strong, diffuse membranous Trop2 expression (3+) in the
carcinomatous component of ovarian MMT. Upper right panel:
Minimal to absent Trop2 expression in normal ovarian surface
epithelium and stroma. Lower left panel: Strong, focal membranous
Trop2 expression (2+) in the carcinomatous component of uterine
MMT. The adjacent sarcomatous component is negative for Trop2.
Lower right panel: Weak, focal Trop2 expression in normal
endometrial glands. (All images 200× original magnification)
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ADCC
Each carcinosarcoma cell line was tested for sensitivity
to natural killer (NK) cell activity by exposure to periph-
eral blood lymphocytes (PBLs) collected from several
healthy donors. Cytotoxicity was measured using a
standard 5 h
51Cr-release assay. Without exception, all
cell lines were found to be highly resistant to NK-
mediated lysis when exposed to PBL with or without
rituximab control antibody at effector: target cell ratios
(E:T) of 25:1 and 50:1 (mean killing 0.9% ± 2.5 SD, Fig-
ure 2 and data not shown). Incubation with hRS7
resulted in a high degree of immune-mediated cell
death in the Trop-2 overexpressing cell line (OMMT-
ARK-2, mean of 37.7%, range of 34.7-41.0%; P <0 . 0 0 1 ) ,
while a low cytotoxic effect was detected against the low
Trop-2 expressing cell line (UMMT-ARK-1, mean 5.7%,
range: 4.4-6.7%; P = 0.02; Figure 2). Consistent with the
negligible Trop-2 expression seen by qRT-PCR and flow
cytometry (Table 3), UMMT-ARK-2 and OMMT-ARK-
1 demonstrated no significant killing after incubation
with PBL with hRS7 (data not shown).
Effect of Complement and Physiologic Concentrations of
IgG on hRS7-mediated ADCC
The OMMT-ARK-2 cell line was evaluated for sensitiv-
ity to complement-mediated cytotoxicity and for possi-
ble inhibition of ADCC by physiological concentrations
Table 2 IHC Results for Trop-2 Protein Expression in
UMMT and OMMT
Patients UMMT OMMT
PT 1 3+ 0
PT 2 0 3+
PT 3 2+ 2+
PT 4 0 0
PT 5 0 0
PT 6 0 0
PT 7 0 1+
PT 8 0 0
PT 9 2+ 0
PT 10 0 3+
PT 11 3+ 1+
PT 12 0 3+
PT 13 0 2+
PT 14 0 2+
PT 15 1+
PT 16 1+
PT 17 0
PT 18 3+
PT 19 0
PT 20 0
PT 21 0
PT 22 0
PT 23 2+
PT 24 0
PT 25 2+
PT 26 0
Table 3 Trop-2 mRNA and Protein Expression in
Carcinosarcoma Cell Lines
Cell Line RT-PCR
1 Flow cytometry
Cells (%) MFI
2
Control NEC
3 1--
Control NOVA
4 1--
UMMT ARK-1 65.7 100 20
UMMT ARK-2 0.5 0 0
OMMT ARK-1 0.1 0 0
OMMT ARK-2 13032 100 151
1RT-PCR - Real-time Polymerase Chain Reaction
2 MFI - Mean Fluorescence Intensity
3 NEC - Normal Endometrial Cells
4 NOVA - Normal Ovarian Cells
Figure 2 Representative cytotoxicity experiments against the
low Trop-2 expressing cell line. UMMT-ARK-1 (2 a) and the high
Trop-2 expressing cell line OMMT-ARK-2 (2 b) at different effector to
target cell ratios in the presence or absence of hRS7 in a 5 h
51Cr-
release cytotoxicity assay. Consistent with their Trop-2 expression
levels, low degrees of ADCC was detected against UMMT-ARK-1
while a high degree of ADCC was detected against the OMMT-ARK-
2 cell line. Negligible cytotoxicity was detectable in the absence of
hRS7 or in the presence of rituximab control antibody against both
cell lines.
Raji et al. Journal of Experimental & Clinical Cancer Research 2011, 30:106
http://www.jeccr.com/content/30/1/106
Page 5 of 7of IgG. Human plasma (with or without heat inactiva-
tion) was added in the presence or absence of the effec-
tor cells and hRS7 in a 1:2 ratio, with the degree of cell
lysis evaluated via 5 h
51Cr-release assays. Addition of
plasma with or without hRS7 was unable to induce sig-
nificant cytotoxicity against OMMT-ARK-2 cells in the
absence of PBL (data not shown). However, incubation
of plasma with PBL in the presence of hRS7 consistently
increased hRS7-mediated cytotoxicity against OMMT-
ARK-2 when compared to incubation with PBL alone (P
= 0.002, Figure 3). Addition of physiologic concentra-
tions of IgG (heat-inactivated plasma in a 1:2 ratio) to
PBL in the presence of hRS7 did not significantly
decrease hRS7-mediated killing (P = 0.95) when com-
pared to incubation without plasma (Figure 3), suggest-
ing that the presence of non-specific IgG does not alter
the ability of hRS7 to mediate ADCC in Trop-2 expres-
sing carcinosarcoma cells.
Discussion
In this study, we have investigated Trop-2 expression
and localization by immunohistochemistry in uterine
and ovarian carcinosarcomas and compared these find-
ings to normal endometrium and ovarian control tis-
sues. We have evaluated Trop-2 expression in multiple
biologically aggressive, chemotherapy-resistant carcino-
sarcoma cell lines. Additionally, we have tested the sen-
sitivity of these primary cell lines to immune-mediated
cell death in the presence of hRS7, a humanized Trop-2
mAb made by grafting the complementary-determining
regions of its murine counterpart (mRS7) onto human
IgG1 framework regions [11,13-15]. To our knowledge,
this is the first time that Trop-2 protein has been
demonstrated to be significantly upregulated in human
carcinosarcomas from the uterus (UMMT) and ovary
(OMMT), with negligible expression being detected in
normal ovarian and uterine tissues. Significantly, Trop-2
positivity was confined to the epithelial component of
the carcinosarcomas, without exception.
Although the relationship between high Trop-2
expression and the aggressiveness of human epithelial
neoplasms remains unclear, there is evidence that Trop-
2 functions in the transduction of cell signals regulating
tumor cell growth and resistance to apoptosis. Trop-2
possesses cytoplasmic serine and tyrosine phosphoryla-
tion sites and might function as a cell signal transducer
and regulator of tumor cell growth while increasing
tumor cell resistance to apoptosis [16]. Consistent with
this, Trop-2 has been identified as an oncogene, impli-
cated in colon cancer tumor growth, migration, and
invasion, which suggests that Trop-2- specific targeting
may inhibit tumor cell growth, migration and invasion
[17]. Several human cancers have been shown to express
a bicistronic CYCLIN D1-TROP2 mRNA chimera that
acts as an oncogene and is able to induce aggressive
tumor growth [18]. These observations support the pos-
sibility that aberrant Trop-2 expression contributes to
the enhanced biologic aggressiveness of multiple human
cancers, including carcinosarcomas.
Importantly, in this study we have tested the capability
of hRS7 to induce immune-mediated killing of primary
uterine and ovarian carcinosarcoma cell lines that
express increased levels of Trop-2. Two of the four cell
lines available to this study, one uterine and one ovar-
ian, were found have elevatedTrop-2 expression, with
one cell line (OMMT-ARK-2) expressing high Trop-2
mRNA relative expression by PCR as well as high sur-
face level Trop-2 protein expression by flow cytometry.
This highly expressing cell line was found to have corre-
sponding high sensitivity to hRS7-mediated ADCC,
while negligible killing was detected in the presence of
allogeneic PBL in the absence of hRS7 or in the pre-
sence of rituximab, used as a control antibody. These
results suggest that uterine and ovarian carcinosarco-
mas, which are notoriously resistant to multiple clini-
cally available chemotherapeutic agents [5,6], can be
made highly sensitive to immune-mediated cytotoxicity
when effector cells are engaged by the Trop-2-specific
antibody, hRS7.
In vivo, ADCC applications are known to be depen-
dent upon the availability of the effector cells (mainly
natural killer cells) to interact with the antibody at the
target site in the presence of high concentrations of irre-
levant human IgG. In this study, we show that ADCC
Figure 3 Representative cytotoxicity experiments against the
OMMT-ARK-2 cell line. Cytotoxicity in the presence of human
plasma diluted 1:2 (with or without heat-inactivation) with effector
cells and either hRS7 or rituximab control antibody in 5 h
51Cr-
release assays. Addition of untreated plasma (diluted 1:2) to PBL in
the presence of hRS7 significantly increased the ADCC achieved in
the presence of hRS7 and PBL against OMMT-ARK-2 (P = 0.002).
Addition of physiological concentrations of IgG (i.e. heat-inactivated
plasma diluted 1:2) to PBL in the presence of hRS7 did not
significantly alter the degree of ADCC achieved against OMMT-ARK-
2 in the presence of hRS7 and PBL (P = 0.95).
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by high concentrations (up to 50%) of human plasma. In
fact, a consistent increase in cytotoxicity was detected in
the presence of effector cells and non-heat-inactivated
human plasma. This suggests that in the presence of
effector PBL, human plasma may augment hRS7-
mediated cytotoxicity against carcinosarcomas. More-
over, these results indicate that the binding of hRS7 to
the Fc receptor on mononuclear effector cells is likely to
occur in the in vivo setting.
Conclusions
I nc o n c l u s i o n ,t h i si st h ef i r s tr e p o r to nT r o p - 2p r o t e i n
expression and hRS7 antibody-dependent cellular cyto-
toxicity in uterine and ovarian carcinosarcomas. We
report Trop-2 overexpression in 35% of uterine and 57%
of the ovarian carcinosarcoma tested by IHC and in two
out of four primary carcinosarcoma cell lines available
to this study, and we have provided evidence that
increased surface expression of Trop-2 is associated
with increased cancer cell susceptibility to immune-
mediated cytotoxicity in the presence of hRS7. Although
in vivo data will ultimately be necessary to validate the
therapeutic potential of hRS7 against Trop-2-expressing
carcinosarcomas, our in vitro results suggest that target-
ing cancer cells with high surface expression of Trop-2
may be an effective way to treat residual or resistant
uterine and ovarian carcinosarcomas.
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